CN104169275B - 用作激酶抑制剂的三唑取代的吡啶化合物 - Google Patents
用作激酶抑制剂的三唑取代的吡啶化合物 Download PDFInfo
- Publication number
- CN104169275B CN104169275B CN201380013640.XA CN201380013640A CN104169275B CN 104169275 B CN104169275 B CN 104169275B CN 201380013640 A CN201380013640 A CN 201380013640A CN 104169275 B CN104169275 B CN 104169275B
- Authority
- CN
- China
- Prior art keywords
- solvent
- acn
- isopropylamino
- pyridin
- retention time
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 Nc1cc(N=C*2)c2cc1 Chemical compound Nc1cc(N=C*2)c2cc1 0.000 description 10
- YXBSPEDTBVJVAY-UHFFFAOYSA-N C1=CN=[I]C=C1 Chemical compound C1=CN=[I]C=C1 YXBSPEDTBVJVAY-UHFFFAOYSA-N 0.000 description 1
- FMIYUKBRIPHXTI-WAYWQWQTSA-N C=C/C=C\NC=C Chemical compound C=C/C=C\NC=C FMIYUKBRIPHXTI-WAYWQWQTSA-N 0.000 description 1
- KZPSPKJOYAPXIR-UHFFFAOYSA-N C=CCNc1cc(Cl)ncc1-c1nc(C(O)=O)c[s]1 Chemical compound C=CCNc1cc(Cl)ncc1-c1nc(C(O)=O)c[s]1 KZPSPKJOYAPXIR-UHFFFAOYSA-N 0.000 description 1
- JSADXPHJQCCHLN-ZDUSSCGKSA-N CC(C)Nc(cc(Nc1cc2n[s]nc2cc1)nc1)c1-c1nnc(C(N(CC2)C[C@H]2O)=O)[s]1 Chemical compound CC(C)Nc(cc(Nc1cc2n[s]nc2cc1)nc1)c1-c1nnc(C(N(CC2)C[C@H]2O)=O)[s]1 JSADXPHJQCCHLN-ZDUSSCGKSA-N 0.000 description 1
- WKZRODSIPZVFDQ-UHFFFAOYSA-N CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1cnc[o]1 Chemical compound CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1cnc[o]1 WKZRODSIPZVFDQ-UHFFFAOYSA-N 0.000 description 1
- LTPHABUONTVSMY-UHFFFAOYSA-N CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1nc(C(C)=O)c(C)[s]1 Chemical compound CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1nc(C(C)=O)c(C)[s]1 LTPHABUONTVSMY-UHFFFAOYSA-N 0.000 description 1
- GVEJPAHQTPJBEZ-UHFFFAOYSA-N CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1nc(N(C(C)=O)C(OC(C)(C)C)=O)c(C)[o]1 Chemical compound CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1nc(N(C(C)=O)C(OC(C)(C)C)=O)c(C)[o]1 GVEJPAHQTPJBEZ-UHFFFAOYSA-N 0.000 description 1
- CBUCTFVPFDVFSU-UHFFFAOYSA-N CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1nnc(C(CO)NS(C)(=O)=O)[o]1 Chemical compound CC(C)Nc(cc(Nc1ccc2nc[s]c2c1)nc1)c1-c1nnc(C(CO)NS(C)(=O)=O)[o]1 CBUCTFVPFDVFSU-UHFFFAOYSA-N 0.000 description 1
- LXPRJDMMMSEHQG-UHFFFAOYSA-N CC(C)Nc1cc(Cl)ncc1-c1nc(C(O)=O)c(C)[s]1 Chemical compound CC(C)Nc1cc(Cl)ncc1-c1nc(C(O)=O)c(C)[s]1 LXPRJDMMMSEHQG-UHFFFAOYSA-N 0.000 description 1
- DVIAFXIRVDBBFQ-UHFFFAOYSA-N CC(C)Nc1cc(Cl)ncc1C(NC(CO)C(OC)=O)=O Chemical compound CC(C)Nc1cc(Cl)ncc1C(NC(CO)C(OC)=O)=O DVIAFXIRVDBBFQ-UHFFFAOYSA-N 0.000 description 1
- UNUSCOSCJACYLL-UHFFFAOYSA-N CC(C)Nc1cc(Nc2ccc3nc[s]c3c2)ncc1-c1nnc(C(N(CC2)CC2NS(C)(=O)=O)=O)[s]1 Chemical compound CC(C)Nc1cc(Nc2ccc3nc[s]c3c2)ncc1-c1nnc(C(N(CC2)CC2NS(C)(=O)=O)=O)[s]1 UNUSCOSCJACYLL-UHFFFAOYSA-N 0.000 description 1
- YYRRNJVZTIDJOM-SREVYHEPSA-N CCC/C=N\OC=C Chemical compound CCC/C=N\OC=C YYRRNJVZTIDJOM-SREVYHEPSA-N 0.000 description 1
- NPTVZUXYHNHOJK-UHFFFAOYSA-N CCOC(c(c(NC(C)C)c1)cnc1Cl)=O Chemical compound CCOC(c(c(NC(C)C)c1)cnc1Cl)=O NPTVZUXYHNHOJK-UHFFFAOYSA-N 0.000 description 1
- NQPWPRGYGNULNY-CYBMUJFWSA-N CNC(c(cc1)ccc1Nc1cc(Cl)ncc1-c1nnc(C(N(CC2)C[C@@H]2O)=O)[s]1)=O Chemical compound CNC(c(cc1)ccc1Nc1cc(Cl)ncc1-c1nnc(C(N(CC2)C[C@@H]2O)=O)[s]1)=O NQPWPRGYGNULNY-CYBMUJFWSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586139P | 2012-01-13 | 2012-01-13 | |
| US61/586,139 | 2012-01-13 | ||
| PCT/US2013/021096 WO2013106614A1 (en) | 2012-01-13 | 2013-01-11 | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104169275A CN104169275A (zh) | 2014-11-26 |
| CN104169275B true CN104169275B (zh) | 2017-06-09 |
Family
ID=47595098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201380013640.XA Expired - Fee Related CN104169275B (zh) | 2012-01-13 | 2013-01-11 | 用作激酶抑制剂的三唑取代的吡啶化合物 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8987311B2 (https=) |
| EP (1) | EP2802577B1 (https=) |
| JP (1) | JP6096807B2 (https=) |
| CN (1) | CN104169275B (https=) |
| ES (1) | ES2630705T3 (https=) |
| WO (1) | WO2013106614A1 (https=) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2802576B1 (en) | 2012-01-13 | 2018-06-27 | Bristol-Myers Squibb Company | Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors |
| CN104254533B (zh) * | 2012-01-13 | 2017-09-08 | 百时美施贵宝公司 | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 |
| WO2014058685A1 (en) | 2012-10-08 | 2014-04-17 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| KR20150079963A (ko) | 2012-11-08 | 2015-07-08 | 브리스톨-마이어스 스큅 컴퍼니 | 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물 |
| CN104781251B (zh) * | 2012-11-08 | 2016-12-14 | 百时美施贵宝公司 | 可作为激酶调节剂的经双环杂环取代的吡啶基化合物 |
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| DK3300500T3 (da) | 2015-05-20 | 2020-05-18 | Amgen Inc | Triazolagonister af apj-receptoren |
| WO2016210036A1 (en) | 2015-06-24 | 2016-12-29 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
| ES2822956T3 (es) * | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
| TW201718571A (zh) | 2015-06-24 | 2017-06-01 | 必治妥美雅史谷比公司 | 經雜芳基取代之胺基吡啶化合物 |
| WO2017192485A1 (en) | 2016-05-03 | 2017-11-09 | Amgen Inc. | Heterocyclic triazole compounds as agonists of the apj receptor |
| CN106222183B (zh) * | 2016-07-25 | 2019-11-08 | 南通大学 | 靶向人irak1基因的小干扰rna及其应用 |
| EP3848370B1 (en) * | 2016-10-14 | 2025-05-07 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| WO2018093579A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Triazole phenyl compounds as agonists of the apj receptor |
| US11020395B2 (en) | 2016-11-16 | 2021-06-01 | Amgen Inc. | Cycloalkyl substituted triazole compounds as agonists of the APJ receptor |
| EP3541792B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole furan compounds as agonists of the apj receptor |
| EP3541803B1 (en) | 2016-11-16 | 2020-12-23 | Amgen Inc. | Triazole pyridyl compounds as agonists of the apj receptor |
| US11046680B1 (en) | 2016-11-16 | 2021-06-29 | Amgen Inc. | Heteroaryl-substituted triazoles as APJ receptor agonists |
| WO2018093576A1 (en) | 2016-11-16 | 2018-05-24 | Amgen Inc. | Alkyl substituted triazole compounds as agonists of the apj receptor |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| PE20191817A1 (es) | 2017-05-11 | 2019-12-27 | Bristol Myers Squibb Co | Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4) |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| US11149040B2 (en) | 2017-11-03 | 2021-10-19 | Amgen Inc. | Fused triazole agonists of the APJ receptor |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| EP3728228A1 (en) | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CN110317190A (zh) * | 2018-03-28 | 2019-10-11 | 首都医科大学 | 一种三唑-羧酸酯类衍生物在医药领域的应用 |
| WO2019213006A1 (en) | 2018-05-01 | 2019-11-07 | Amgen Inc. | Substituted pyrimidinones as agonists of the apj receptor |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| TWI842978B (zh) * | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN114127075B (zh) | 2019-07-18 | 2024-05-14 | 百时美施贵宝公司 | 可用作IRAK4抑制剂的吡唑并[3,4-d]吡咯并[1,2-b]哒嗪基化合物 |
| EP3999508B1 (en) | 2019-07-18 | 2023-08-30 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| JP7573596B2 (ja) | 2019-07-23 | 2024-10-25 | ブリストル－マイヤーズ スクイブ カンパニー | Ｉｒａｋ４阻害剤として有用なチエノピリジニルおよびチアゾロピリジニル化合物 |
| WO2021026181A1 (en) | 2019-08-06 | 2021-02-11 | Bristol-Myers Squibb Company | Bicyclic heterocyclic compounds useful as irak4 inhibitors |
| ES3059914T3 (en) | 2019-08-13 | 2026-03-24 | Bristol Myers Squibb Co | Bicyclic heteroaryl compounds useful as irak4 inhibitors |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021158495A1 (en) | 2020-02-03 | 2021-08-12 | Bristol-Myers Squibb Company | Benzo[5,6][1,4]dioxino[2,3-b]pyridine compounds useful as irak4 inhibitors |
| EP4100408B1 (en) | 2020-02-03 | 2024-02-28 | Bristol-Myers Squibb Company | Tricyclic heteroaryl compounds useful as irak4 inhibitors |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| MX2023003698A (es) * | 2020-09-30 | 2023-06-15 | Asahi Kasei Pharma Corp | Compuesto biciclico que contiene nitrogeno y pirimidina. |
| PH12023500015A1 (en) | 2020-12-30 | 2024-03-11 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| US12187744B2 (en) | 2021-10-29 | 2025-01-07 | Kymera Therapeutics, Inc. | IRAK4 degraders and synthesis thereof |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| WO2026005537A1 (ko) * | 2024-06-28 | 2026-01-02 | 주식회사 대웅제약 | 신규한 화합물, 및 이를 포함하는 암 또는 자가 면역 질환의 예방 또는 치료용 약학적 조성물 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004065378A1 (en) * | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| WO2005013982A1 (en) * | 2003-08-06 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
| CN1625400A (zh) * | 2002-02-01 | 2005-06-08 | 里格尔药品股份有限公司 | 2,4－嘧啶二胺化合物及其用途 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6825190B2 (en) | 2001-06-15 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Protein kinase inhibitors and uses thereof |
| AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
| GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
| AU2003244098A1 (en) | 2002-06-28 | 2004-01-19 | Yamanouchi Pharmaceutical Co., Ltd. | Diaminopyrimidinecarboxa mide derivative |
| CA2531401A1 (en) | 2003-07-10 | 2005-01-27 | Neurogen Corporation | Substituted heterocyclic diarylamine analogues |
| GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
| US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
| FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
| KR20100020454A (ko) | 2007-06-08 | 2010-02-22 | 바이엘 크롭사이언스 소시에떼아노님 | 살진균제 헤테로사이클릴-피리미디닐-아미노 유도체 |
| WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
| GB0719644D0 (en) * | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| TW201028381A (en) * | 2008-07-14 | 2010-08-01 | Shionogi & Co | Pyridine derivative having ttk inhibition activity |
| EP2440204B1 (en) | 2009-06-12 | 2013-12-18 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
| DE102009033208A1 (de) * | 2009-07-15 | 2011-01-20 | Merck Patent Gmbh | Aminopyridinderivate |
| EP2493863B1 (en) | 2009-10-30 | 2015-02-25 | Janssen Pharmaceutica NV | Phenoxy-substituted pyrimidines as opioid receptor modulators |
| KR20120130104A (ko) | 2010-02-01 | 2012-11-28 | 닛뽕 케미파 가부시키가이샤 | Ｇｐｒ119 작동약 |
| CN103619854A (zh) | 2011-04-29 | 2014-03-05 | 西奈山伊坎医学院 | 激酶抑制剂 |
-
2013
- 2013-01-11 WO PCT/US2013/021096 patent/WO2013106614A1/en not_active Ceased
- 2013-01-11 ES ES13700829.8T patent/ES2630705T3/es active Active
- 2013-01-11 US US14/371,281 patent/US8987311B2/en active Active
- 2013-01-11 JP JP2014552312A patent/JP6096807B2/ja not_active Expired - Fee Related
- 2013-01-11 CN CN201380013640.XA patent/CN104169275B/zh not_active Expired - Fee Related
- 2013-01-11 EP EP13700829.8A patent/EP2802577B1/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1625400A (zh) * | 2002-02-01 | 2005-06-08 | 里格尔药品股份有限公司 | 2,4－嘧啶二胺化合物及其用途 |
| WO2004065378A1 (en) * | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
| WO2005013982A1 (en) * | 2003-08-06 | 2005-02-17 | Vertex Pharmaceuticals Incorporated | Aminotriazole compounds useful as inhibitors of protein kinases |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6096807B2 (ja) | 2017-03-15 |
| US8987311B2 (en) | 2015-03-24 |
| JP2015503621A (ja) | 2015-02-02 |
| US20150045347A1 (en) | 2015-02-12 |
| CN104169275A (zh) | 2014-11-26 |
| EP2802577A1 (en) | 2014-11-19 |
| ES2630705T3 (es) | 2017-08-23 |
| EP2802577B1 (en) | 2017-03-01 |
| WO2013106614A1 (en) | 2013-07-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104169275B (zh) | 用作激酶抑制剂的三唑取代的吡啶化合物 | |
| CN104159896B (zh) | 用作激酶抑制剂的杂环取代的吡啶基化合物 | |
| CN104254533B (zh) | 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物 | |
| AU2018217488B2 (en) | Aminotriazolopyridines as kinase inhibitors | |
| JP6215338B2 (ja) | キナーゼモジュレーターとして有用な二環式ヘテロ環置換ピリジル化合物 | |
| US11618753B2 (en) | Aminopyrrolotriazines as kinase inhibitors | |
| AU2018361249B2 (en) | Aminoimidazopyridazines as kinase inhibitors | |
| KR20210106441A (ko) | 사이클릭 우레아 | |
| EP4463452B1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20170609 |